NCT06838429View on ClinicalTrials.gov

PARPi and Ovarian Cancer Survival

Not yet recruitingOBSERVATIONAL
Enrollment

6,000

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Epithelial Ovarian Cancer, Fallopian Tube or PeritoneumPARP Inhibitor
All Listed Sponsors
collaborator

Institute for Ovarian Cancer, Fudan University; Department of Gynecologic Oncology, Cancer Center, Fudan University Zhongshan Hospital, Shanghai, China

UNKNOWN

collaborator

Department of Gynecologic Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China

UNKNOWN

collaborator

Department of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Sun Yat-sen University

UNKNOWN

collaborator

Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China

UNKNOWN

lead

Shanghai Gynecologic Oncology Group

OTHER_GOV